CN115960204B - Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 - Google Patents

Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 Download PDF

Info

Publication number
CN115960204B
CN115960204B CN202211379445.6A CN202211379445A CN115960204B CN 115960204 B CN115960204 B CN 115960204B CN 202211379445 A CN202211379445 A CN 202211379445A CN 115960204 B CN115960204 B CN 115960204B
Authority
CN
China
Prior art keywords
tcr
cancer
cells
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211379445.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115960204A (zh
Inventor
彭松明
安多
钟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinjing Zhiyuan Biotechnology Suzhou Co ltd
Original Assignee
Xinjing Zhiyuan Biotechnology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinjing Zhiyuan Biotechnology Suzhou Co ltd filed Critical Xinjing Zhiyuan Biotechnology Suzhou Co ltd
Priority to CN202211379445.6A priority Critical patent/CN115960204B/zh
Priority to CN202311283184.2A priority patent/CN117430689A/zh
Priority to JP2025526492A priority patent/JP2025537239A/ja
Priority to PCT/CN2023/078124 priority patent/WO2024093056A1/zh
Priority to EP23884004.5A priority patent/EP4613762A1/en
Priority to AU2023371349A priority patent/AU2023371349A1/en
Publication of CN115960204A publication Critical patent/CN115960204A/zh
Application granted granted Critical
Publication of CN115960204B publication Critical patent/CN115960204B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CN202211379445.6A 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 Active CN115960204B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202211379445.6A CN115960204B (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN202311283184.2A CN117430689A (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
JP2025526492A JP2025537239A (ja) 2022-11-04 2023-02-24 Ｋｒａｓ＿ｇ１２ｖ変異抗原特異的ｔｃｒ、並びに、斯かるｔｃｒ及びｃｄ８を共発現する再指向化ｃｄ４ ｔ細胞
PCT/CN2023/078124 WO2024093056A1 (zh) 2022-11-04 2023-02-24 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
EP23884004.5A EP4613762A1 (en) 2022-11-04 2023-02-24 Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8
AU2023371349A AU2023371349A1 (en) 2022-11-04 2023-02-24 Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211379445.6A CN115960204B (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311283184.2A Division CN117430689A (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Publications (2)

Publication Number Publication Date
CN115960204A CN115960204A (zh) 2023-04-14
CN115960204B true CN115960204B (zh) 2023-08-25

Family

ID=87362539

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211379445.6A Active CN115960204B (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN202311283184.2A Pending CN117430689A (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311283184.2A Pending CN117430689A (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Country Status (5)

Country Link
EP (1) EP4613762A1 (https=)
JP (1) JP2025537239A (https=)
CN (2) CN115960204B (https=)
AU (1) AU2023371349A1 (https=)
WO (1) WO2024093056A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN120518771A (zh) * 2024-02-20 2025-08-22 上海信谱生物医药科技有限公司 一种识别kras突变的t细胞受体及其编码序列

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836638A (zh) * 2017-12-04 2020-10-27 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
CN112300269A (zh) * 2020-09-29 2021-02-02 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
CN112646024A (zh) * 2019-10-10 2021-04-13 广东香雪精准医疗技术有限公司 一种识别kras突变的t细胞受体及其编码序列

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836638A (zh) * 2017-12-04 2020-10-27 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
CN112646024A (zh) * 2019-10-10 2021-04-13 广东香雪精准医疗技术有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112300269A (zh) * 2020-09-29 2021-02-02 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Also Published As

Publication number Publication date
CN115960204A (zh) 2023-04-14
EP4613762A1 (en) 2025-09-10
WO2024093056A1 (zh) 2024-05-10
CN117430689A (zh) 2024-01-23
JP2025537239A (ja) 2025-11-14
AU2023371349A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CN115960204B (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
US20240066064A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
TW201928052A (zh) 靶向ny-eso-1的基因修飾免疫細胞及其用途
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
US20220211758A1 (en) Affinity maturated t cell receptors and use thereof
KR20200035104A (ko) Braf 특이적 tcr 및 그의 용도
CN116715750B (zh) 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞
KR20250024533A (ko) Ras 신생 항원에 특이적인 결합 단백질 및 이의 용도
CN120157754A (zh) Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
KR20230010597A (ko) 트랜스포존 시스템 및 이의 용도
CN116731155B (zh) 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
CN118165098A (zh) 特异性识别egfr l858r突变抗原的tcr及其用途
HK40086029B (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
HK40086029A (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
HK40101993A (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
HK40099427A (zh) 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞
HK40099427B (zh) 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞
US20230288400A1 (en) T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
US20230288405A1 (en) T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
US20230287346A1 (en) T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
HK40106146A (zh) 使用溶瘤病毒递送正交il-2选择性刺激实体瘤中的t细胞
CN121046318A (zh) 一种改进的t细胞及其用途
HK40111554A (zh) 使用细胞穿透crispr-cas系统在原代免疫细胞中进行基因编辑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40086029

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant